Form 4: Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells Shares to Cover Tax Obligations

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On March 5, 2024, Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, sold 4,135 shares of common stock at a weighted average price of $18.7279.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Klee directly owns 2,959,308 shares of Amylyx Pharmaceuticals.
• The shares were sold in multiple transactions at prices ranging from $18.62 to $18.82.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations, which is a common practice and doesn't necessarily reflect a change in the insider's view of the company's prospects. The large number of shares still held by the Co-CEO is a positive sign.

Industry Context

Form 4 filings are a routine part of insider trading activity and are closely watched by investors for signals about management's confidence in the company's prospects. Sales to cover tax obligations are common and don't necessarily indicate a negative outlook.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the explanation provided mitigates this concern.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be minimal.

Key Dates